Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Sparing of Organs at Risk in High Dose Rate Brachytherapy

24 juli 2013 uppdaterad av: Centre Oscar Lambret

Prospective Study on the Sparing of Organs at Risk in High Dose Rate Brachytherapy for Cervix Cancer

Cervix carcinoma is a common malignancy. Radiation therapy still remains a major treatment for patients with carcinoma cervix. Conventional treatment with radiation therapy includes a combination of external beam radiation therapy and intracavitary treatment. Low dose rate intracavitary brachytherapy treatment is already well studied. But high dose rate brachytherapy is a relatively new alternative.

In brachytherapy, major developments have been made in the integration of 3D imaging and computerized 3D treatment planning. Medical imaging improvements allowed for better definition of tumoral volumes and organs at risk.

The GYN GEC-ESTRO published recommendations on the 3D imaging for better characterization of these volumes. Improvements in CT-SCan and lately in RMN had lead to a better definition of volums of interest (tumor and his extensions and organs at risk : bladder, rectum, sigmoidis, small bowels). RMN is the imaging standard in the evaluation of tumoral extension in cervix cancer. However its use is not easy in many brachytherapy departments.

This study will evaluate the feasibility and sparing of organs at risk for high dose rate brachytherapy if volume delineation is done at each of the two sessions performed with 3D RMN.

Studieöversikt

Status

Avslutad

Betingelser

Cervical Carcinoma Stage IB to IV

Detaljerad beskrivning

After 60 Gy are delivered with Intensity Modulated Radiation Therapy (IMRT), the brachytherapy in high dose rate will deliver 15 Gy to the CTVhr (high risk CTV) in two sessions.

A clinical examination and an RMN are performed at the end of the external radiation to evaluate the residual tumoral volume. Two HDR brachytherapy sessions are then performed.

During the first session, a CT-Scan and an RMN will be performed after the fletcher application. A second CT-Scan will be performed during the second treatment session to create new volumes and to improve organs at risk sparing.

Studietyp

Observationell

Inskrivning (Faktisk)

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Frankrike
- - Lille, Frankrike, 59020
    - Centre Oscar Lambret

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Kvinna

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients with indication of HDR brachytherapy in cervix carcinoma of stage IB to II.

After realization of external radiation therapy done (60 Gy in IMRT)

Beskrivning

Inclusion Criteria:

Cervix carcinoma stage Ib to IV (FIGO)
OMS < 2
Tomography by positron emission and/or chirurgical staging before the external radiotherapy
RMN before the starting of treatment and at the end af external radiotherapy
Patient information
Validation of the indication af high dose rate brachytherapy
External radiation therapy (60 Gy with IMRT)

Exclusion Criteria:

No external radiation therapy
Surgery in the 4 weeks before before the inclusion
Prior pelvic radiation therapy
intestinal inflammatory disease or active pathology
active infection or severe pathology didn't allow the treatment
Prior carcinoma in the last 5 years (except cutaneous carcinoma or in situ carcinoma)
Inclusion in another clinical trial

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Vad mäter studien?

Primära resultatmått

Resultatmått	Åtgärdsbeskrivning	Tidsram
Evaluation of the sparing of organs at risk with a delineation at each session and the CTVhr volume modification Tidsram: At 8 weeks of external radiotherapy	To record the irradiated volumes modifications of each OAR at each session and the CTV volume modification.	At 8 weeks of external radiotherapy

Sekundära resultatmått

Resultatmått	Åtgärdsbeskrivning	Tidsram
Evaluation of medical imaging with CT-Scan and RMN for cervix cancer Tidsram: At 8 weeks of external radiotherapy	Interest of RMN sequences Water and T2 for the definition of volumes Evaluation of imaging registration on the planning treatment system based on the brachytherapy applicator for the precision of volumes delineation Evaluate the interest of TDM and RMN for volumes delineation	At 8 weeks of external radiotherapy

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Centre Oscar Lambret

Utredare

Studierektor: Philippe Nickers, MD, PhD, Centre Oscar Lambret

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 juni 2011

Primärt slutförande (Faktisk)

1 februari 2013

Avslutad studie (Faktisk)